ArticleJournal of immunology research2026
Chaiyin Granules Improve Acute Lung Injury by Regulating Gut Microbiota and Unsaturated Fatty Acid Mediated Wnt/β-Catenin Signaling Pathway.
Article in Journal of immunology research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Chaiyin Granules Improve Acute Lung Injury by Regulating Gut Microbiota and Unsaturated Fatty Acid Mediated Wnt/β-Catenin Signaling Pathway.Journal of immunology research · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
aim of studyThis study aimed to investigate the efficacy and mechanism of Chaiyin granules (CY) in improving acute lung injury (ALI) based on the gut-lung axis. MATERIALS AND
methodsUHPLC-ESI-Q-Exactive Orbitrap MS was used to analyze the active ingredients of CY. Establishment of lipopolysaccharide (LPS)-induced ALI mouse model and grouping: control, model, CYL (1.56 g/kg), CYM (3.12 g/kg), CYH (6.24 g/kg), and Dex (2 mg/kg) groups. The lung index and wet/dry (W/D) weight ratio of the lungs were calculated. The pathological damage of lung tissue was detected and evaluated using hematoxylin-eosin (H&E) staining. The expression of various inflammatory factors and oxidative stress-related factors was detected using cytometric bead array (CBA) and enzyme-linked immunosorbent assay (ELISA), respectively. The indicators characterizing intestinal barrier damage were detected through the application of Alcian blue periodic acid Schiff (AB-PAS) staining, ELISA, and western blot. Furthermore, gut microbiota were analyzed by 16S rRNA, and serum and lung metabolites were analyzed by metabolomics. Finally, proteomics was applied to enrich key signaling pathways, and western blot was used to validate the relevant proteins.
resultsFifty-five active components in CY were identified. The pharmacological results showed that CY significantly alleviated lung pathological injury and inflammatory response of lung tissue in ALI mice while improving the integrity of intestinal structure and the permeability of the mucosal barrier in ALI mice. The evaluation was based on the improvement of abnormal expression of inflammatory factors, oxidative stress factors, tight junction proteins, goblet cells, LPS, secretory immunoglobulin A (SIgA), diamine oxidase (DAO), and D-lactic acid (D-LA), to a certain extent. Furthermore, 16S rRNA and metabolomics results showed that multiple core bacterial genera and unsaturated fatty acids were involved during CY treatment. Finally, proteomic results indicated that the Wnt/β-catenin pathway was the mechanism of action for CY treatment of ALI, and CY effectively regulated the protein levels of Wnt3a, β-catenin, and phosphorylated glycogen synthase kinase-3β (p-GSK3β).
conclusionThis study confirmed that CY could exert pharmacological effects on improving ALI mice through the gut-lung axis and also found that core bacterial genera and unsaturated fatty acids were involved in this process. More importantly, the Wnt/β-catenin signaling pathway had been identified as a key signaling pathway for CY to alleviate ALI.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.